Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results

Key Points

• Kymera reported a quarterly EPS loss of $1.32, missing the consensus estimate of a $1.26 loss. The company posted a negative net margin of 285.33% and negative return on equity of 21.22%.
• Clinical progress remained positive: KT-579 achieved more than 90% IRF5 degradation in top-dose cohorts with a favorable safety profile, while KT-621 atopic dermatitis results are expected by year-end. Kymera is targeting a lupus Phase Ib study by early 2027 and potentially a Phase III atopic dermatitis trial by mid-2027.
• Kymera ended September with approximately $1.6 billion in cash and investments, providing projected funding through 2029. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $135.12.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.06), FiscalAI reports. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. During the same period last year, the firm earned ($0.94) earnings per share. Kymera Therapeutics's revenue for the quarter was up .0% compared to the same quarter last year.

Here are the key takeaways from Kymera Therapeutics' conference call:

• KT-579 showed robust human proof of mechanism: once-daily dosing produced more than 90% IRF5 degradation in the top dose cohorts, including comparable effects in skin, with substantial reductions across inflammatory cytokine, interferon, and B-cell pathways.
• KT-579 was well tolerated in the phase I study, with a safety profile comparable to placebo, no serious adverse events, no discontinuations, and no infection imbalance. Kymera plans to advance the program into the approximately 30-patient LUMORA phase Ib lupus trial by early 2027.
• The company completed the 16-week placebo-controlled portion of the KT-621 BROADEN2 atopic dermatitis study and expects to report results by year-end; 98% of eligible patients entered the 52-week open-label extension. Kymera is preparing for a potential phase III AD study beginning by mid-2027, subject to supportive results and FDA alignment.
• KT-621 asthma enrollment is progressing as planned, with phase IIb BREADTH results expected in late 2027, while partner programs KT-485 and KT-200 also remain on track. Management emphasized potential expansion into additional type 2 inflammatory diseases, but detailed plans will depend on upcoming clinical data.
• Kymera ended September with approximately $1.6 billion in cash and investments, providing a projected runway into 2029 and funding planned KT-621 phase III preparations, the KT-579 lupus study, and continued pipeline research without near-term financing pressure.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR traded down $0.80 during mid-day trading on Thursday, reaching $121.71. 645,629 shares of the company's stock were exchanged, compared to its average volume of 746,868. Kymera Therapeutics has a twelve month low of $55.66 and a twelve month high of $130.05. The firm has a market capitalization of $10.12 billion, a price-to-earnings ratio of -37.53 and a beta of 1.98. The business's fifty day moving average price is $114.92 and its 200-day moving average price is $95.84.

Analyst Upgrades and Downgrades

KYMR has been the topic of several research reports. Piper Sandler restated an "overweight" rating and issued a $140.00 price target on shares of Kymera Therapeutics in a research note on Wednesday, September 23rd. Wolfe Research upgraded shares of Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $180.00 price objective for the company in a research note on Thursday, September 10th. Royal Bank Of Canada downgraded shares of Kymera Therapeutics from an "outperform" rating to a "sector perform" rating and boosted their price objective for the company from $106.00 to $115.00 in a report on Monday, July 13th. Barclays increased their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Finally, TD Cowen raised shares of Kymera Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $135.12.

Insider Buying and Selling

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brian Adams sold 6,371 shares of the business's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the transaction, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. This trade represents a 11.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 15.98% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell's natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company's research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.